6815.TWO Diamond Biotechnology Co., Ltd
- Market cap
- TWD 750M
- P/E
- -
- P/B
- 1.36x
- ROE
- -13.0%
- Dividend yield
- 0.88%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6815.TWO undervalued?
Graham numberThe Graham number of Diamond Biotechnology Co., Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Diamond Biotechnology Co., Ltd fundamental analysis
No fundamental analysis for Diamond Biotechnology Co., Ltd yet.
Diamond Biotechnology Co., Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Diamond Biotechnology Co., Ltd
Diamond Biotechnology Co., Ltd engages in the research, development, manufacture, and sale of health care products and medical consumables in Taiwan and internationally. The company offers Miracle Thread, an absorbable synthetic surgical suture device made of polydioxanone; UTIMS, a high-intensity focused ultrasound; Letybo, a frozen crystal injection; TEOSYAL RHA invisible resilient hyaluronic acid; Ronkyla, a sodium deoxycholate injection; S+DIAMOND skincare products. It a…
Full company profileDiamond Biotechnology Co., Ltd financial statements
Diamond Biotechnology Co., Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 268M | 306M | 395M | 435M | 616M | 768M | 501M |
| Gross Profit | 135M | 128M | 188M | 184M | 290M | 331M | 155M |
| Operating Income | 56.3M | 15.0M | 48.1M | 46.4M | 63.9M | 113M | -74.2M |
| EBITDA | 79.1M | 70.8M | 113M | 99.0M | 116M | 131M | -45.9M |
| Net Income | 44.2M | 11.0M | 41.9M | 33.4M | 46.7M | 73.2M | -70.3M |
| EPS | 1.92 | 0.41 | 1.51 | 1.20 | 1.50 | 2.33 | -1.78 |
| Balance Sheet | |||||||
| Total Assets | 470M | 438M | 541M | 630M | 799M | 1.06B | 869M |
| Total Liabilities | 1.74M | 206M | 268M | 328M | 453M | 433M | 327M |
| Shareholders' Equity | 250M | 232M | 273M | 303M | 346M | 623M | 542M |
| Cash & Short-term Investments | 56.5M | 62.4M | 51.2M | 98.5M | 78.5M | 246M | 146M |
| Total Debt | 117M | 151M | 180M | 215M | 353M | 252M | - |
| Cash Flow | |||||||
| Operating Cash Flow | 23.2M | 71.2M | 5.65M | 158M | 40.9M | 33.7M | -2.09M |
| Capital Expenditure | 16.6M | 57.0M | 24.9M | 73.0M | 197M | 30.2M | 1.13M |
| Free Cash Flow | 6.60M | 14.2M | -19.3M | 84.6M | -156M | 3.50M | -3.22M |
| Ratios | |||||||
| ROE | 17.6% | 4.8% | 15.3% | 11.0% | 13.5% | 11.7% | -13.0% |
| ROA | 9.4% | 2.5% | 7.7% | 5.3% | 5.9% | 6.9% | -8.1% |
| Net Profit Margin | 16.5% | 3.6% | 10.6% | 7.7% | 7.6% | 9.5% | -14.0% |
| Debt to Equity | 0.47x | 0.65x | 0.66x | 0.71x | 1.02x | 0.40x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Diamond Biotechnology Co., Ltd dividends
- Dividend yield
- 0.88%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 27, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 6.57M | 0.17 | - |
| 2024 | TWD 4.95M | 0.16 | 6.8% |
| 2023 | TWD 3.02M | 0.10 | 6.5% |
| 2022 | TWD 3.81M | 0.14 | 11.4% |
| 2021 | TWD 994K | 0.04 | 2.4% |
| 2020 | 29.3M | 1.09 | 265.0% |
| 2019 | 36.3M | 1.58 | 82.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1176.017:1000 on Aug 27, 2025.
Who owns Diamond Biotechnology Co., Ltd
Ownership data of Diamond Biotechnology Co., Ltd is not available yet.
Diamond Biotechnology Co., Ltd company profile
- Company name
- Diamond Biotechnology Co., Ltd
- Ticker
- 6815.TWO
- ISIN
- TW0006815004
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Fiscal year end
- December
- Address
- No. 95, Section 1, Taipei, Taiwan, 221
- Phone
- 886 2 2755 3320
- Website
- diamond-biotechnology.cc
About Diamond Biotechnology Co., Ltd
Diamond Biotechnology Co., Ltd engages in the research, development, manufacture, and sale of health care products and medical consumables in Taiwan and internationally. The company offers Miracle Thread, an absorbable synthetic surgical suture device made of polydioxanone; UTIMS, a high-intensity focused ultrasound; Letybo, a frozen crystal injection; TEOSYAL RHA invisible resilient hyaluronic acid; Ronkyla, a sodium deoxycholate injection; S+DIAMOND skincare products. It also sells and leases medical equipment. The company was founded in 2014 and is based in Taipei, Taiwan.
Diamond Biotechnology Co., Ltd management
2- Jiaxian XieGM & Director
- Ting Yu ZhangAccounting Supervisor